Stephanie van Hoppe

18 Chapter 1 22. Tang SC, Nguyen LN, Sparidans RW, et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar, Int J Cancer, 6 (2014) 1484-1494. 10.1002/ijc.28475 23. Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo- controlled trial of the Eastern Cooperative Oncology Group 3999, Blood, 20 (2010) 4077-4085. 10.1182/ blood-2010-04-277269 24. Dash RP, Jayachandra Babu R, Srinivas NR. Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies, Eur J Drug Metab Pharmacokinet, 6 (2017) 915-933. 10.1007/s13318-017-0411-4 25. O’Brien FE, Dinan TG, Griffin BT, et al. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings, Br J Pharmacol, 2 (2012) 289-312. 10.1111/j.1476-5381.2011.01557.x 26. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria, Proc Natl Acad Sci U S A, 24 (2002) 15649- 15654. 10.1073/pnas.202607599 27. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs, Cell, 4 (1994) 491-502. 28. Li W, Sparidans RW, Wang Y, et al. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability, Pharmacol Res, (2018) 47-55. 10.1016/j.phrs.2018.09.020 29. Salphati L, Heffron TP, Alicke B, et al. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier, Clin Cancer Res, 22 (2012) 6239-6248. 10.1158/1078-0432. CCR-12-0720